Paratek Pharmaceuticals Inc   (PRTK)
Other Ticker:  
Price: $2.2300 $0.04 1.826%
Day's High: $2.24 Week Perf: 1.83 %
Day's Low: $ 2.19 30 Day Perf: 2.53 %
Volume (M): 4,764 52 Wk High: $ 2.91
Volume (M$): $ 10,625 52 Wk Avg: $2.06
Open: $2.19 52 Wk Low: $1.29

 Market Capitalization (Millions $) 127
 Shares Outstanding (Millions) 57
 Employees 200
 Revenues (TTM) (Millions $) 167
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc is a US-based biopharmaceutical company that develops innovative therapies for the treatment of infectious diseases and other serious conditions. The company was founded in 1996 with a focus on developing antibiotics to address the growing problem of antibiotic-resistant bacteria.

The company's lead product is NUZYRA, a once-daily oral and intravenous antibiotic that is approved for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is unique in that it is effective against a wide range of bacteria, including those that are resistant to other antibiotics, such as MRSA.

In addition to NUZYRA, Paratek is also developing a second antibiotic, SEYSARA, for the treatment of acne vulgaris. SEYSARA is a once-daily oral antibiotic that targets a specific type of bacteria that is commonly associated with acne.

Paratek has a strong pipeline of additional antibiotics in development, including drugs targeting gram-negative bacteria, which are notoriously difficult to treat. The company's approach to drug development is focused on using innovative technologies and approaches to discover and develop drugs that are effective against drug-resistant bacteria.

Paratek has partnerships and collaborations with a number of academic and commercial organizations, including the US Department of Defense, which is funding the development of a new class of antibiotics for use in biodefense.

The company is headquartered in Boston, Massachusetts, and has additional offices in King of Prussia, Pennsylvania, and Zug, Switzerland. Paratek has a workforce of approximately 160 employees.

Overall, Paratek Pharmaceuticals is a pioneering biopharmaceutical company that is committed to developing innovative therapies for the treatment of infectious diseases and other serious conditions. With a strong pipeline of antibiotics in development and a focus on using cutting-edge technologies and approaches to drug discovery, Paratek is poised to make a significant impact on the field of antibiotic development and change the way we treat drug-resistant infections.

   Company Address: 75 Park Plaza Boston 2116 MA
   Company Phone Number: 807-6600   Stock Exchange / Ticker: NASDAQ PRTK
   PRTK is expected to report next financial results on March 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.


Paratek Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com